Champions Oncology, Inc. (CSBR)
- Previous Close
7.97 - Open
8.27 - Bid 7.74 x 100
- Ask 7.84 x 100
- Day's Range
7.74 - 8.44 - 52 Week Range
3.60 - 11.99 - Volume
16,624 - Avg. Volume
44,372 - Market Cap (intraday)
110.2M - Beta (5Y Monthly) 0.46
- PE Ratio (TTM)
17.60 - EPS (TTM)
0.45 - Earnings Date Jul 16, 2025 - Jul 21, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.00
Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. The company markets its products through internet, word of mouth, and sales force to pharmaceutical and biotechnology companies. Champions Oncology, Inc. was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. The company was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
www.championsoncology.comRecent News: CSBR
View More
Performance Overview: CSBR
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CSBR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CSBR
View MoreValuation Measures
Market Cap
109.51M
Enterprise Value
112.74M
Trailing P/E
17.60
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.89
Price/Book (mrq)
20.02
Enterprise Value/Revenue
1.92
Enterprise Value/EBITDA
13.38
Financial Highlights
Profitability and Income Statement
Profit Margin
10.97%
Return on Assets (ttm)
14.64%
Return on Equity (ttm)
376.84%
Revenue (ttm)
58.59M
Net Income Avi to Common (ttm)
6.43M
Diluted EPS (ttm)
0.45
Balance Sheet and Cash Flow
Total Cash (mrq)
3.2M
Total Debt/Equity (mrq)
117.70%
Levered Free Cash Flow (ttm)
-3.45M
Research Analysis: CSBR
View MoreResearch Reports: CSBR
View MoreDaily – Vickers Top Buyers & Sellers for 01/16/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/12/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/11/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/09/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.